1. Home
  2. ACAD vs CENT Comparison

ACAD vs CENT Comparison

Compare ACAD & CENT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACAD
  • CENT
  • Stock Information
  • Founded
  • ACAD 1993
  • CENT 1955
  • Country
  • ACAD United States
  • CENT United States
  • Employees
  • ACAD N/A
  • CENT N/A
  • Industry
  • ACAD Biotechnology: Pharmaceutical Preparations
  • CENT Consumer Specialties
  • Sector
  • ACAD Health Care
  • CENT Consumer Discretionary
  • Exchange
  • ACAD Nasdaq
  • CENT Nasdaq
  • Market Cap
  • ACAD 2.8B
  • CENT 2.4B
  • IPO Year
  • ACAD 2004
  • CENT N/A
  • Fundamental
  • Price
  • ACAD $14.73
  • CENT $34.80
  • Analyst Decision
  • ACAD Buy
  • CENT Strong Buy
  • Analyst Count
  • ACAD 16
  • CENT 3
  • Target Price
  • ACAD $23.93
  • CENT $45.00
  • AVG Volume (30 Days)
  • ACAD 1.8M
  • CENT 349.1K
  • Earning Date
  • ACAD 05-07-2025
  • CENT 05-07-2025
  • Dividend Yield
  • ACAD N/A
  • CENT N/A
  • EPS Growth
  • ACAD N/A
  • CENT N/A
  • EPS
  • ACAD 1.36
  • CENT 1.82
  • Revenue
  • ACAD $957,797,000.00
  • CENT $3,222,363,000.00
  • Revenue This Year
  • ACAD $13.07
  • CENT $2.77
  • Revenue Next Year
  • ACAD $9.88
  • CENT $2.16
  • P/E Ratio
  • ACAD $10.83
  • CENT $19.08
  • Revenue Growth
  • ACAD 31.85
  • CENT N/A
  • 52 Week Low
  • ACAD $13.40
  • CENT $32.17
  • 52 Week High
  • ACAD $20.68
  • CENT $47.48
  • Technical
  • Relative Strength Index (RSI)
  • ACAD 38.07
  • CENT 44.10
  • Support Level
  • ACAD $14.34
  • CENT $34.58
  • Resistance Level
  • ACAD $15.18
  • CENT $37.45
  • Average True Range (ATR)
  • ACAD 0.80
  • CENT 1.53
  • MACD
  • ACAD -0.02
  • CENT -0.02
  • Stochastic Oscillator
  • ACAD 38.22
  • CENT 32.42

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

About CENT Central Garden & Pet Company

Central Garden & Pet Co understands that home is central to life and has nurtured happy and healthy homes for over forty years. The segments of the company are the pet segment and garden segment. The company's trusted products are dedicated to helping lawns grow greener, gardens bloom bigger, pets live healthier and communities grow stronger. Central is home to a portfolio of more than sixty-five brands including Pennington, Nylabone, Kaytee, Amdro, and Aqueon, manufacturing and distribution capabilities, and a passionate, entrepreneurial growth culture. Central Garden and Pet is based in Walnut Creek, California, and has offices across North America and Europe.

Share on Social Networks: